One main reason might be the administration of multiple ALK inhibitor and chemotherapy lines, because more different types and lines of treatment have been linked to longer survival in both ALK+NSCLC and LCNEC (Elsayed et al. 2021; Fisch et al. 2021). This evidence concerns the gene ALK and large cell neuroendocrine carcinoma.